Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DR310 is a preclinical-stage bispecific antibody-drug conjugate (BsAb-ADC) developed by Doer Biologics for the treatment of solid tumors. It is designed to target the epidermal growth factor receptor (EGFR) along with an undisclosed second target. By utilizing a bispecific antibody format conjugated to a cytotoxic payload, DR310 aims to selectively deliver therapeutic agents to tumor cells expressing both targets, potentially enhancing efficacy and reducing off-target toxicities compared to conventional therapies. The candidate is currently in the preclinical candidate (PCC) stage of development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DR310.